Please use this identifier to cite or link to this item:
Title: Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases – prospective data from a multi-site Australian registry.
Author: Wong, Vanessa
de Boer, R.
Dunn, C.
Anton, A.
Malik, L.
Greenberg, S.
Yeo, B.
Nott, L.
Collins, I.
Torres, J.
Barnett, F.
Nottage, M.
Gibbs, P.
Wen Lok, S.
Issue Date: 2022
Publication Title: Internal Medicine Journal
Volume: 52
Start Page: 1707
End Page: 1716
Abstract: Background International practice guidelines recommend administration of bone-modifying agents (BMA) in metastatic breast cancer (MBC) patients with bone metastases to reduce skeletal-related events (SRE). Optimal delivery of BMA in routine clinical practice, including agent selection and prescribing intervals, remains unclear. Aim To describe real-world practice of Australian breast oncologists. Methods Prospective data from February 2015 to July 2020 on BMA delivery to MBC patients with bone metastases was analysed from Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Australian Patient (TABITHA), a multi-site Australian HER2+ MBC registry. Results Of 333 HER2+ MBC patients, 171 (51%) had bone metastases at diagnosis, with a mean age of 58.1 years (range, 32–87). One hundred and thirty (76%) patients received a BMA, with 90 (69%) receiving denosumab and 40 (31%) receiving a bisphosphonate. Patients who received a BMA were more likely to have received concurrent first-line systemic anti-HER2 therapy (95% vs 83%; P = 0.04), to present with bone-only metastases at diagnosis (24% vs 7%; P = 0.02) and less likely to have visceral metastases (51% vs 71%; P = 0.03). Ten of 40 (25%) bisphosphonate patients and 45 of 90 (50%) denosumab patients received their BMA at the recommended 4-weekly interval. Prescribing intervals varied over time. Adverse events reported were consistent with clinical trial data. Conclusion Three-quarters of Australian HER2+ MBC patients with bone metastases receive a BMA, often at different schedules than guidelines recommend. Further studies, including all MBC subtypes, are warranted to better understand clinicians' prescribing rationale and potential consequences of current prescribing practice on SRE incidence.
Internal ID Number: 02057
Health Subject: BREAST CANCER
Type: Journal Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.